INCLUSION CRITERIA:

• Written informed consent
• Diagnosis of RRMM and/or plasma cell dyscrasias and:
  • Has failed 4 prior therapies
  • Is refractory to and IMID and to a proteasome inhibitor and to an anti CD-38 antibody (alone or in combinations if available)
• Disease Progression on last therapy
• Able to obtain ophthalmic examinations at baseline, before the subsequent 3 treatment cycles and as clinically indicated
• Contraception requirements
  • Female Participants: A female patient is eligible to participate if one of the following conditions applies:
    • The patient Is not a woman of childbearing potential (WOCBP)OR
    • The patient Is a WOCBP and using an effective contraceptive method during treatment with belantamab mafodotin and for 4 months after the last dose. The patient must also have a negative highly sensitive serum pregnancy test within 72 hours of dosing on C1D1. Please discuss with GSK physician if the patient is pregnant, breast-feeding or planning to have a baby.
  • Male participants with female partners of child-bearing potential are eligible to participate if they agree to use effective contraception during treatment with belantamab mafodotin until 6 months after the last dose

EXCLUSION CRITERIA:

• Evidence of Active Bleeding
• Currently Active GVHD
• Known Hypersensitivity to the active substance or to any of the excipients
• Previous progression on belantamab mafodotin

US Expanded Access (group) Protocol:

INCLUSION CRITERIA:

For patients currently receiving BLENREP through the REMS program

• Patients currently enrolled in the BLENREP REMS program who have received at least 1 dose of BLENREP
• Written informed consent can be obtained from the patient or legally authorized representative as per local regulations

For new patients

• New patients diagnosed with RRMM who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent
• No other treatment options available
• Written informed consent can be obtained from the patient or legally authorized representative as per local regulations

EXCLUSION CRITERIA:

For patients currently receiving BLENREP through the REMS program

• Previously progressed on treatment with belantamab mafodotin.
• Patient is pregnant or breastfeeding

For new patients

• Previously progressed on treatment with belantamab mafodotin.
• Patient is pregnant or breastfeeding